The fact that everything looks different doesn't mean that all has changed...
Biblio
] . VEGFR-3 Ligands and Lymphangiogenesis [Internet]. University of Helsinki. 2002. http://ethesis.helsinki.fi/julkaisut/mat/bioti/vk/jeltsch
Michael Jeltsch, PhD Thesis, 2002 (1.75 MB)
Michael Jeltsch, PhD Thesis, 2002 (1.75 MB). VEGF-C: The evolutionary origin, activation, and potential as a drug target [Internet]. [Helsinki. Finland]: University of Helsinki; 2023. http://hdl.handle.net/10138/357923 Rauniyar - 2023 - VEGF-C: The evolutionary origin, activation, and potential as a drug target (3.09 MB)
Rauniyar - 2023 - VEGF-C: The evolutionary origin, activation, and potential as a drug target (3.09 MB). Mechanism of VEGF-C Activation and Effect on Lymphatic Vessel Growth and Regeneration [Internet]. [Helsinki, Finland]: University of Helsinki; 2020. https://helda.helsinki.fi/handle/10138/314714 Jha - 2020 - Mechanism of VEGF-C Activation and Effect on Lymphatic Vessel Growth and Regeneration (1.96 MB)
Jha - 2020 - Mechanism of VEGF-C Activation and Effect on Lymphatic Vessel Growth and Regeneration (1.96 MB). Functional Analysis of VEGF-B and VEGF-C [Internet]. University of Helsinki. [Helsinki]: Univeristy of Helsinki; 1997. http://urn.fi/URN:NBN:fi-fe977347 Michael Jeltsch, MSc Thesis, 1997 (3.12 MB)
Michael Jeltsch, MSc Thesis, 1997 (3.12 MB). VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. Journal of Heart and Lung Transplantation. 2011;30:S118 - S118.
. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development [Internet]. 1996;122(12):3829 - 37. http://view.ncbi.nlm.nih.gov/pubmed/9012504 Eola Kukk et al., Development 1996 (805.94 KB)
Eola Kukk et al., Development 1996 (805.94 KB). VEGF-C Protects the Integrity of Bone Marrow Perivascular Niche. Blood [Internet]. 2020;:accepted - for publication. https://ashpublications.org/blood/article/doi/10.1182/blood.2020005699/463465/VEGF-C-Protects-the-Integrity-of-Bone-Marrow Fang et al. 2020 - VEGF-C protects the integrity of bone marrow perivascular niche (6 MB)
Fang et al. 2020 - VEGF-C protects the integrity of bone marrow perivascular niche (6 MB). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol [Internet]. 2003;161(6):1163 - 77. http://view.ncbi.nlm.nih.gov/pubmed/12810700 Holger Gerhardt et al., The Journal of Biological Chemistry 2003 (2.24 MB)
Holger Gerhardt et al., The Journal of Biological Chemistry 2003 (2.24 MB). VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol [Internet]. 1997;188(1):96 - 109. http://view.ncbi.nlm.nih.gov/pubmed/9245515 Su-Ja Oh et al., Developmental Biology 1997 (3.28 MB)
Su-Ja Oh et al., Developmental Biology 1997 (3.28 MB). Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol [Internet]. 1997;173(2):211 - 5. http://view.ncbi.nlm.nih.gov/pubmed/9365524 Vladimir Joukov et al., Journal of Cellular Physiology 1997 (127.57 KB)
Vladimir Joukov et al., Journal of Cellular Physiology 1997 (127.57 KB). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001;20(4):672 - 82. http://view.ncbi.nlm.nih.gov/pubmed/11179212 Stefano Mandriota et al., EMBO Journal 2001 (736.96 KB)
Stefano Mandriota et al., EMBO Journal 2001 (736.96 KB). Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974 Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB)
Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB). Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB)
Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB). Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489 Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB) Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB). Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol [Internet]. 1998;177(3):439 - 52. http://view.ncbi.nlm.nih.gov/pubmed/9808152 Michael Pepper et al., Journal of Cellular Physiology 1998 (689.97 KB)
Michael Pepper et al., Journal of Cellular Physiology 1998 (689.97 KB). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229 Marc Achen et al., PNAS 1998 (447.59 KB)
Marc Achen et al., PNAS 1998 (447.59 KB). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646 Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB). Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A [Internet]. 1998;95(20):11709 - 14. http://view.ncbi.nlm.nih.gov/pubmed/9751730 Birgitta Olofsson et al., PNAS 1998 (470.59 KB)
Birgitta Olofsson et al., PNAS 1998 (470.59 KB). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292 Yulong He et al., Cancer Research 2005 (1.82 MB)
Yulong He et al., Cancer Research 2005 (1.82 MB). The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522 Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Caroline Heckman et al., Cancer Research 2008 (504.8 KB). A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development. 2013;140(7):1497-506. Villefranc 2013 (7.86 MB)
Villefranc 2013 (7.86 MB). Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841 Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Imke Albrecht et al., PLoS One 2010 (3.37 MB). Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstract J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB)
J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB). Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid–Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Applied Materials & Interfaces [Internet]. 2024;16(15):18643 - 18657. https://pubs.acs.org/doi/10.1021/acsami.4c02363 López-Cerdá et al. - 2024 - Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide [...] (7.06 MB)
López-Cerdá et al. - 2024 - Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide [...] (7.06 MB). Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085 Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)